Cell Line News and Research

RSS

Omnia Biologics and Biotech Experts announce deal for manufacturing and process development services

Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and biologics manufacturing and process development consultants Biotech Experts, Inc. (Clarksburg, MD) today announced a deal for manufacturing and process development services.

12 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

Cancer drug may provide an effective secondary treatment for gut tumor

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh Cancer Institute (UPCI). The findings, based on experiments using cell cultures, were published in the Jan. 1 issue of Cancer Research.

12 Jan 2010

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF).

11 Jan 2010

Gene modification of human embryonic stem cells may yield potential treatments for genetic diseases

Biologists have developed an efficient way to genetically modify human embryonic stem cells. Their approach, which uses bacterial artificial chromosomes to swap in defective copies of genes, will make possible the rapid development of stem cell lines that can both serve as models for human genetic diseases and as testbeds on which to screen potential treatments, they say.

8 Jan 2010

Laureate Pharma, Selexis SA collaborate to provide streamlined access to complementary contract services

Laureate Pharma, Inc. a US based biopharmaceutical contract manufacturing organization and Selexis SA, a Swiss based contract developer of high performance production cell lines, jointly announced today their continued collaboration via a joint-marketing relationship. This expanded relationship provides streamlined access to a set of highly complementary contract services.

6 Jan 2010

Scientists develop straightforward technique to find ethnic origin of stem cells

An international team of scientists led by researchers at The Scripps Research Institute has developed a straightforward technique to determine the ethnic origin of stem cells.

30 Dec 2009

TSC proteins regulate Notch activity

Two independent teams of researchers have identified a role for enhanced activation of the signaling protein Notch in tumors characterized by inactivation of either the TSC1 or the TSC2 protein. As indicated by Warren Pear, at the University of Pennsylvania, Philadelphia, in an accompanying commentary, these data provide a rationale for testing whether Notch inhibitors are of benefit to those with TSC-associated tumors.

29 Dec 2009

Nanoscaffolds could play a central role in tissue and organ reconstruction

Researchers from the University of Hong Kong and the Massachusetts Institute of Technology have published a study in the current issue of Cell Transplantation (18:9), now freely available on line at http://www.ingentaconnect.com/content/cog/ct, that explores ways to successfully keep stem cells "forever young" during implantation by slowing their growth, differentiation and proliferation.

28 Dec 2009

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Applied Biosystems, part of Life Technologies Corporation, today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

17 Dec 2009

Human embryonic stem cell lines lack genetic diversity, says study

The most widely used human embryonic stem cell lines lack genetic diversity, a finding that raises social justice questions that must be addressed to ensure that all sectors of society benefit from stem cell advances, according to a University of Michigan research team.

17 Dec 2009

Pistachios can decrease inflammation and cardiovascular disease

New research published online, December 10, 2009 indicates that bioactive compounds in pistachios, and molecules present in pistachios, have anti-inflammatory properties.

17 Dec 2009

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Femta Pharmaceuticals and Lonza Group Ltd jointly announce the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis.

15 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

NIH approves new stem cell lines for research

The National Institutes of Health announced approval of embryonic stem cell lines for federally funded research. The Washington Post reports the decision is "opening the way for millions of taxpayer dollars to be used to conduct research that was put off-limits by President George W. Bush.

3 Dec 2009

TAP and pharma company team up to design Sonata, a unique system to speed drug development

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, is delighted to announce that its Advanced Projects Group has partnered with a leading pharma company to successfully design and deliver Sonata™, a unique system for automated culturing and processing of cell lines in shake flasks.

1 Dec 2009

Whitehead researchers develop new type of genetic screen for human cells

Whitehead researchers have developed a new type of genetic screen for human cells to pinpoint specific genes and proteins used by pathogens, according to their paper in Science.

27 Nov 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

Gonorrhea medication may help fight cancer

Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer.

6 Nov 2009

Nanoparticles may cause DNA damage across a cellular barrier

Scientists have shown in the laboratory that metal nanoparticles damaged the DNA in cells on the other side of a cellular barrier. The nanoparticles did not cause the damage by passing through the barrier, but generated signalling molecules within the barrier cells that were then transmitted to cause damage in cells the other side of the barrier.

5 Nov 2009

Cell Line News and Research

Omnia Biologics and Biotech Experts announce deal for manufacturing and process development services

MedGenesis Therapeutix enters into license agreement with Amgen

Cancer drug may provide an effective secondary treatment for gut tumor

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Gene modification of human embryonic stem cells may yield potential treatments for genetic diseases

Laureate Pharma, Selexis SA collaborate to provide streamlined access to complementary contract services

Scientists develop straightforward technique to find ethnic origin of stem cells

TSC proteins regulate Notch activity

Nanoscaffolds could play a central role in tissue and organ reconstruction

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Human embryonic stem cell lines lack genetic diversity, says study

Pistachios can decrease inflammation and cardiovascular disease

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Preclinical data of Curis' HSP 90 inhibitor published

NIH approves new stem cell lines for research

TAP and pharma company team up to design Sonata, a unique system to speed drug development

Whitehead researchers develop new type of genetic screen for human cells

'Suicide gene E' reduces potent drug dosage in cancer patients

Gonorrhea medication may help fight cancer

Nanoparticles may cause DNA damage across a cellular barrier

How to optimize your cell line development eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News